Rock Creek Group LP acquired a new position in shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 57,201 shares of the biopharmaceutical company’s stock, valued at approximately $420,000. Rock Creek Group LP owned approximately 0.27% of Galmed Pharmaceuticals at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in GLMD. ARK Investment Management LLC boosted its stake in Galmed Pharmaceuticals by 13.4% in the 2nd quarter. ARK Investment Management LLC now owns 60,948 shares of the biopharmaceutical company’s stock valued at $448,000 after buying an additional 7,199 shares in the last quarter. Deutsche Bank AG acquired a new stake in Galmed Pharmaceuticals in the 4th quarter valued at $229,000. Delek Group Ltd. boosted its stake in Galmed Pharmaceuticals by 15.5% in the 2nd quarter. Delek Group Ltd. now owns 24,552 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,300 shares in the last quarter. ETF Managers Group LLC boosted its stake in Galmed Pharmaceuticals by 34.7% in the 2nd quarter. ETF Managers Group LLC now owns 45,222 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 11,649 shares in the last quarter. Finally, Ibex Investors LLC boosted its stake in Galmed Pharmaceuticals by 22.4% in the 2nd quarter. Ibex Investors LLC now owns 807,400 shares of the biopharmaceutical company’s stock valued at $5,934,000 after buying an additional 147,874 shares in the last quarter. 36.81% of the stock is currently owned by institutional investors.
GLMD traded up $0.27 during trading on Thursday, hitting $5.20. The company’s stock had a trading volume of 1,502 shares, compared to its average volume of 90,776. The firm’s 50 day moving average price is $5.19 and its two-hundred day moving average price is $6.76. The company has a quick ratio of 25.69, a current ratio of 25.69 and a debt-to-equity ratio of 0.01. Galmed Pharmaceuticals Ltd has a 12 month low of $4.40 and a 12 month high of $14.65. The stock has a market capitalization of $105.10 million, a price-to-earnings ratio of -9.69 and a beta of 2.74.
GLMD has been the topic of several recent analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of Galmed Pharmaceuticals in a research note on Tuesday, August 6th. Laidlaw initiated coverage on Galmed Pharmaceuticals in a research note on Monday, July 22nd. They issued a “buy” rating and a $25.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, August 6th. Finally, ValuEngine raised Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 28th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $28.17.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Read More: Why do corrections happen?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.